Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Jun 25. pii: e8741. doi: 10.15252/emmm.201708741. [Epub ahead of print]

2.

Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways.

Villeneuve DL, Landesmann B, Allavena P, Ashley N, Bal-Price A, Corsini E, Halappanavar S, Hussell T, Laskin D, Lawrence T, Nikolic-Paterson D, Pallardy M, Paini A, Pieters R, Roth R, Tschudi-Monnet F.

Toxicol Sci. 2018 Jun 1;163(2):346-352. doi: 10.1093/toxsci/kfy047.

PMID:
29850905
3.

Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy.

Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, Campi E, Allavena P, Pesce S, Villa S, Avuzzi B, Morlino S, Visentin ME, Zaffaroni N, Rancati T, Valdagni R.

Dis Markers. 2018 Feb 25;2018:9128128. doi: 10.1155/2018/9128128. eCollection 2018.

4.

Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.

Borgoni S, Iannello A, Cutrupi S, Allavena P, D'Incalci M, Novelli F, Cappello P.

Oncoimmunology. 2017 Nov 13;7(2):e1393596. doi: 10.1080/2162402X.2017.1393596. eCollection 2018.

PMID:
29308326
5.

Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition.

Siddiqui I, Erreni M, Kamal MA, Porta C, Marchesi F, Pesce S, Pasqualini F, Schiarea S, Chiabrando C, Mantovani A, Allavena P.

Oncoimmunology. 2017 Nov 1;7(2):e1388485. doi: 10.1080/2162402X.2017.1388485. eCollection 2018.

PMID:
29308316
6.

FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis.

Chattaragada MS, Riganti C, Sassoe M, Principe M, Santamorena MM, Roux C, Curcio C, Evangelista A, Allavena P, Salvia R, Rusev B, Scarpa A, Cappello P, Novelli F.

Oncogene. 2018 Feb 8;37(6):697-709. doi: 10.1038/onc.2017.358. Epub 2017 Oct 23.

7.

Targeting tumor associated macrophages: The new challenge for nanomedicine.

Andón FT, Digifico E, Maeda A, Erreni M, Mantovani A, Alonso MJ, Allavena P.

Semin Immunol. 2017 Dec;34:103-113. doi: 10.1016/j.smim.2017.09.004. Epub 2017 Sep 21. Review.

PMID:
28941641
8.

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.

Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M.

Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6.

9.

Heme-oxygenase-1 Production by Intestinal CX3CR1+ Macrophages Helps to Resolve Inflammation and Prevents Carcinogenesis.

Marelli G, Erreni M, Anselmo A, Taverniti V, Guglielmetti S, Mantovani A, Allavena P.

Cancer Res. 2017 Aug 15;77(16):4472-4485. doi: 10.1158/0008-5472.CAN-16-2501. Epub 2017 Jun 15.

PMID:
28619710
10.

Inflammation as target in cancer therapy.

Marelli G, Sica A, Vannucci L, Allavena P.

Curr Opin Pharmacol. 2017 Aug;35:57-65. doi: 10.1016/j.coph.2017.05.007. Epub 2017 Jun 12. Review.

PMID:
28618326
11.

Tumour-associated macrophages as treatment targets in oncology.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P.

Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. doi: 10.1038/nrclinonc.2016.217. Epub 2017 Jan 24. Review.

12.

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M.

Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.

13.

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.

Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R.

Dis Model Mech. 2016 Dec 1;9(12):1461-1471. Epub 2016 Oct 20.

14.

Non-redundant role of the chemokine receptor CX3CR1 in the anti-inflammatory function of gut macrophages.

Marelli G, Belgiovine C, Mantovani A, Erreni M, Allavena P.

Immunobiology. 2017 Feb;222(2):463-472. doi: 10.1016/j.imbio.2016.07.013. Epub 2016 Aug 2.

PMID:
27707514
15.

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.

PMID:
27251642
16.

Correction: Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer.

Di Caro G, Carvello M, Pesce S, Erreni M, Marchesi F, Todoric J, Sacchi M, Montorsi M, Allavena P, Spinelli A.

PLoS One. 2016 May 26;11(5):e0156669. doi: 10.1371/journal.pone.0156669. eCollection 2016.

17.

Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment.

Liguori M, Buracchi C, Pasqualini F, Bergomas F, Pesce S, Sironi M, Grizzi F, Mantovani A, Belgiovine C, Allavena P.

Oncotarget. 2016 Jul 5;7(27):41662-41676. doi: 10.18632/oncotarget.9340.

18.

Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma.

Castino GF, Cortese N, Capretti G, Serio S, Di Caro G, Mineri R, Magrini E, Grizzi F, Cappello P, Novelli F, Spaggiari P, Roncalli M, Ridolfi C, Gavazzi F, Zerbi A, Allavena P, Marchesi F.

Oncoimmunology. 2015 Sep 11;5(4):e1085147. eCollection 2016 Apr.

19.

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient.

Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P.

J Immunother Cancer. 2016 Apr 19;4:21. doi: 10.1186/s40425-016-0125-1. eCollection 2016.

20.

Tumor-associated macrophages and anti-tumor therapies: complex links.

Belgiovine C, D'Incalci M, Allavena P, Frapolli R.

Cell Mol Life Sci. 2016 Jul;73(13):2411-24. doi: 10.1007/s00018-016-2166-5. Epub 2016 Mar 8. Review.

PMID:
26956893
21.

Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer.

Di Caro G, Carvello M, Pesce S, Erreni M, Marchesi F, Todoric J, Sacchi M, Montorsi M, Allavena P, Spinelli A.

PLoS One. 2016 Feb 9;11(2):e0148186. doi: 10.1371/journal.pone.0148186. eCollection 2016. Erratum in: PLoS One. 2016;11(5):e0156669.

22.

The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination.

Erreni M, Siddiqui I, Marelli G, Grizzi F, Bianchi P, Morone D, Marchesi F, Celesti G, Pesce S, Doni A, Rumio C, Roncalli MG, Laghi L, Mantovani A, Allavena P.

J Immunol. 2016 Jan 15;196(2):902-14. doi: 10.4049/jimmunol.1501335. Epub 2015 Dec 16.

23.

Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.

Belli C, Piemonti L, D'Incalci M, Zucchetti M, Porcu L, Cappio S, Doglioni C, Allavena P, Ceraulo D, Maggiora P, Dugnani E, Cangi MG, Garassini G, Reni M.

Cancer Chemother Pharmacol. 2016 Mar;77(3):477-84. doi: 10.1007/s00280-015-2932-3. Epub 2015 Dec 14.

PMID:
26666646
24.

Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.

Infante M, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, Roncalli M, Cavuto S, Pesce S, Monari M, Valaperta S, Montanelli A, Solomon D, Bottoni E, Errico V, Voulaz E, Bossi M, Chiesa G, Passera E, Mantovani A, Alloisio M.

Int J Cancer. 2016 Feb 15;138(4):983-91. doi: 10.1002/ijc.29822. Epub 2015 Sep 8.

25.

Macrophage polarization in pathology.

Sica A, Erreni M, Allavena P, Porta C.

Cell Mol Life Sci. 2015 Nov;72(21):4111-26. doi: 10.1007/s00018-015-1995-y. Epub 2015 Jul 26. Review.

PMID:
26210152
26.

Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.

Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F.

Gut. 2016 Oct;65(10):1710-20. doi: 10.1136/gutjnl-2015-309193. Epub 2015 Jul 8.

PMID:
26156960
27.

The interaction of anticancer therapies with tumor-associated macrophages.

Mantovani A, Allavena P.

J Exp Med. 2015 Apr 6;212(4):435-45. doi: 10.1084/jem.20150295. Epub 2015 Mar 9. Review.

28.

Corrigendum: Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells.

Rimoldi M, Chieppa M, Salucci V, Avogadri F, Sonzogni A, Sampietro GM, Nespoli A, Viale G, Allavena P, Rescigno M.

Nat Immunol. 2015 Mar;16(3):326. doi: 10.1038/ni0315-326a. No abstract available.

PMID:
25689446
29.

Pharmacological modulation of monocytes and macrophages.

Mantovani A, Vecchi A, Allavena P.

Curr Opin Pharmacol. 2014 Aug;17:38-44. doi: 10.1016/j.coph.2014.07.004. Epub 2014 Jul 24. Review.

PMID:
25062123
30.

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies.

Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P.

Cancer Immunol Immunother. 2015 Jan;64(1):83-9. doi: 10.1007/s00262-014-1576-1. Epub 2014 Jul 4. Review.

PMID:
24993564
31.

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.

D'Incalci M, Badri N, Galmarini CM, Allavena P.

Br J Cancer. 2014 Aug 12;111(4):646-50. doi: 10.1038/bjc.2014.149. Epub 2014 Apr 22. Review.

32.

Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers.

Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, Laghi L, Allavena P, Mantovani A, Marchesi F.

Clin Cancer Res. 2014 Apr 15;20(8):2147-58. doi: 10.1158/1078-0432.CCR-13-2590. Epub 2014 Feb 12.

33.

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.

Galmarini CM, D'Incalci M, Allavena P.

Mar Drugs. 2014 Jan 27;12(2):719-33. doi: 10.3390/md12020719. Review.

34.

Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis.

Celesti G, Di Caro G, Bianchi P, Grizzi F, Marchesi F, Basso G, Rahal D, Delconte G, Catalano M, Cappello P, Roncalli M, Zerbi A, Montorsi M, Novelli F, Mantovani A, Allavena P, Malesci A, Laghi L.

Br J Cancer. 2013 Oct 29;109(9):2424-33. doi: 10.1038/bjc.2013.565. Epub 2013 Oct 1.

35.
36.

Trabectedin: A drug from the sea that strikes tumor-associated macrophages.

Allavena P, Germano G, Belgiovine C, D'Incalci M, Mantovani A.

Oncoimmunology. 2013 Jun 1;2(6):e24614. Epub 2013 Apr 16.

37.

Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Biswas SK, Allavena P, Mantovani A.

Semin Immunopathol. 2013 Sep;35(5):585-600. doi: 10.1007/s00281-013-0367-7. Epub 2013 May 9. Review.

PMID:
23657835
38.

New activities for the anti-tumor agent trabectedin: taking two birds with one stone.

D'Incalci M, Frapolli R, Germano G, Allavena P.

Oncotarget. 2013 Apr;4(4):496-7. No abstract available.

39.

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M.

Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25.

40.

Immunohistohemical expression of the chemokine fractalkine and its receptor in the human brain cortex after severe traumatic brain injury and brain hemorrhage.

Gaetani P, Pisano P, Solinas G, Colombo P, Destro A, Levi D, Aimar E, Rodriguez R, Baena Y, Allavena P.

J Neurosurg Sci. 2013 Mar;57(1):55-62.

PMID:
23584220
41.

Role of macrophage targeting in the antitumor activity of trabectedin.

Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P.

Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

42.

Human adipose tissue macrophages display activation of cancer-related pathways.

Mayi TH, Daoudi M, Derudas B, Gross B, Bories G, Wouters K, Brozek J, Caiazzo R, Raverdi V, Pigeyre M, Allavena P, Mantovani A, Pattou F, Staels B, Chinetti-Gbaguidi G.

J Biol Chem. 2012 Jun 22;287(26):21904-13. doi: 10.1074/jbc.M111.315200. Epub 2012 Apr 17.

43.

Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system.

Marchesi F, Grizzi F, Laghi L, Mantovani A, Allavena P.

Curr Pharm Des. 2012;18(17):2432-8. Review.

PMID:
22372498
44.

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.

Allavena P, Mantovani A.

Clin Exp Immunol. 2012 Feb;167(2):195-205. doi: 10.1111/j.1365-2249.2011.04515.x. Review.

45.

Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.

Erreni M, Mantovani A, Allavena P.

Cancer Microenviron. 2011 Aug;4(2):141-54. doi: 10.1007/s12307-010-0052-5. Epub 2010 Sep 17.

46.

Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.

Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R.

Thromb Haemost. 2011 Oct;106(4):705-11. doi: 10.1160/TH11-05-0311. Epub 2011 Aug 11.

PMID:
21833453
47.

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.

Germano G, Mantovani A, Allavena P.

Ann Med. 2011 Dec;43(8):581-93. doi: 10.3109/07853890.2011.595732. Epub 2011 Jul 14. Review.

PMID:
21756064
48.

Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.

Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, Mantovani A.

Clin Dev Immunol. 2010;2010:547179. doi: 10.1155/2010/547179. Epub 2011 Feb 9.

49.

Tertiary intratumor lymphoid tissue in colo-rectal cancer.

Bergomas F, Grizzi F, Doni A, Pesce S, Laghi L, Allavena P, Mantovani A, Marchesi F.

Cancers (Basel). 2011 Dec 28;4(1):1-10. doi: 10.3390/cancers4010001.

50.

Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma.

Liguori M, Solinas G, Germano G, Mantovani A, Allavena P.

Cancers (Basel). 2011 Sep 28;3(4):3740-61. doi: 10.3390/cancers3043740.

Supplemental Content

Loading ...
Support Center